Is serum glutathione level in combination with serum PSA useful for early detection of prostatic carcinoma? A local study of Iraq

Ehab Jasim Mohammad


Background: Prostate cancer is the most common cancer and the second leading cause of cancer-related death among men of western countries. The aim of this study is to develop non-invasive diagnostic tools for the early detection of prostate cancer (PCa) through detection of low level of Serum reduced Glutathione (GSH).

Methods: Serum samples from men being evaluated for PCa were analyzed for reduced Glutathione (GSH) level. The results were compared with the prostate needle biopsy findings and (PSA) level combined with Digital Rectal Examination (DRE). Samples were obtained from 59 cases including 18 controls.

Results: The maximum sensitivity of the test was observed in the first category of confirmed cases with 93.33% turs positive detected with low GSH. Among those highly suspected Ca prostate there was 87.5% true positive test and 12.5% false negative results. Among those in grey zone where PSA between is 4 and 10, and DRE is suggestive, the proportion of true positive was 50%.

Conclusions: These results demonstrate that serum reduced Glutathione (GSH) level is helpful in patient with definite carcinoma. This test could be useful in augmenting current PCa diagnostic procedures. For example, the examination test for reduced Glutathione (GSH) level with an elevated prostate- specific antigen level might be used in predicting which patients will have negative biopsies and may be used as treatment modality for PCa.


Glutathione, Molecular marker, Prostate cancer

Full Text:



DeVita, Vincent T. Lawrence, Theodore S. Preface. In: DeVita, Vincent Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clinic. 2014;64:9-29.

Brawer MK, editor. Prostate‐specific antigen. Seminars in surgical oncology; 2000: Wiley Online Library.

Stamey TA, Johnstone IM, McNEAL JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol. 2002;167:103-11.

Pinthus JH, Pacik D, Ramon J. Diagnosis of prostate cancer. Prost Can. Spring. 2007;83-99.

Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Prost Can. Spring. 2007;65-81.

Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urol. 2001;58:843-8.

Yan PY, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 2007;67:8043-50.

Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Nat Cancer Inst. 2001;93:1747-52.

Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clini Can Res. 2001;7:2727-30.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of Prostate Cancer. Jama. 2015;313:390-7.

Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S, et al. Prostate cancer markers: An update. Biomed Rep. 2016;4:263-8.

Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol. 2002;167:1854-8.

Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008;68:1777-85.

Whitfield J. Gamma glutamyl transferase. Critical reviews in clinical laboratory sciences. 2001;38:263-355.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-54.